- Net sales reached $656.4M (+0.5% reported YoY), with Clinical Diagnostics up 2.7% and Life Science down 2.8%.
- GAAP diluted EPS shifted to $17.02 versus a loss of $12.70 in the prior-year period.
- Operating cash flows were lower YoY at $303.2M vs $367.3M.
Why is $BIO moving today? · SEC 8-K archive
$BIO SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $BIO: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $BIO filing catalyst
Why did $BIO trigger an AI stock catalyst alert?
$BIO triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +1.5/10). Headline: Bio-Rad Reports Q3 Revenue of $656.4M, GAAP Net Income Swings to $458.6M. Key points: - Net sales reached $656.4M (+0.5% reported YoY), with Clinical Diagnostics up 2.7% and Life Science down 2.8%. - GAAP diluted EPS shifted to $17.02 versus a loss of $12.70 in the prior-year period. - Operating cash flows were lower YoY at $303.2M vs $367.3M.
How did $BIO stock react after the SEC filing?
After the SEC 8-K for $BIO, observed market reaction: T0 price $379.99. Past moves do not guarantee future results.
Where can I get real-time $BIO SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $BIO via Telegram and the VIP Web Terminal from €10/month.